IMR Press / FBL / Volume 18 / Issue 2 / DOI: 10.2741/4113

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

CD133+ cancer stem cells in lung cancer

Show Less
1 Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
Academic Editor:Wei Qin
Front. Biosci. (Landmark Ed) 2013, 18(2), 447–453; https://doi.org/10.2741/4113
Published: 1 January 2013
(This article belongs to the Special Issue Pathogenesis and diagnostic modalities in cancer)
Abstract

Lung cancer is the most preventable cancer worldwide but has a poor prognosis. Recent advances in the study of lung cancer stem cell (CSC) populations has led to a growing recognition of the central importance of cells with stem cell-like properties in lung tumorigenesis. High number of CD133+ cells is associated with the maintenance, metastasis and drug-resistance of lung cancer. CD133 serves as a stemness biomarker for CD133+ CSCs, which have been found in lung cancer tissues. This article reviews the major studies supporting the existence and importance of CD133+ CSCs in the maintenance, metastasis and drug resistance of lung cancer. Continued research in the field of CD133+ CSCs biology is vital, as ongoing efforts promise to yield new prognostic and therapeutic targets.


Keywords
Cancer Stem Cell
Non-Small Cell Lung Cancer
Hematopoietic Stem
Progenitor Cells
Review
Share
Back to top